Disease relevance of Spon2

• Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer [1].
• Hyporesponsiveness was abrogated by BCG infection or by the presence of the M-16/C tumour, but not by the presence of the Spon-2 tumour [2].
• Peritoneal macrophages from C3H/HeN mice bearing subcutaneous M-16/C or Spon-2 mammary carcinomas had enhanced tumouricidal activity over control macrophages from non-tumour bearers in response to 5,6-dimethylxanthenone-4-acetic acid (5,6-MeXAA), a novel antitumour agent which has been scheduled for clinical evaluation [2].

High impact information on Spon2

• Moreover, mindin binds directly to bacteria and their components and functions as an opsonin for macrophage phagocytosis of bacteria [3].
• Mindin(-/-) mice displayed defective CD4(+) T-cell priming and impaired humoral immune responses to T-dependent antigens [4].
• DCs lacking beta(1) integrin had reduced adhesion to mindin matrix, decreased expression of Rac1/2 and impaired priming capacity [4].
• The adhesion of neutrophils to mindin is blocked by anti-integrin alpha4, anti-integrin alpha(M), and anti-integrin beta2 antibodies [5].
• Mindin/RG-1 protein expression is maintained in >80% of prostate cancers metastatic to bone or lymph nodes as well as in locally recurrent tumors in androgen-unresponsive patients [1].

Anatomical context of Spon2

• In response to LPS at low concentrations, or to 5,6-MeXAA at all concentrations, tumouricidal activity from macrophages from Spon-2-bearing C3H/HeJ mice was severely depressed compared with activity from their C3H/HeN counterparts [2].
• Macrophages from Spon-2 tumour bearing mice behaved like "primed" thioglycollate-elicited macrophages and produced a tumouricidal response to 5,6-MeXXA which was significantly higher than that obtained from resident peritoneal macrophages from non-tumour bearing mice [2].

Associations of Spon2 with chemical compounds

• Similarly in C3H/HeN mice, cortisone pre-treatment prevented FAA-induced necrosis of Spon-2 and partially prevented necrosis induction in mammary M-16/C tumours [6].

Analytical, diagnostic and therapeutic context of Spon2

• A fully human antibody, 19G9, was generated against mindin/RG-1 protein and was shown to accumulate at high abundance in LNCaP tumor xenografts [1].

References